Fidia signed a binding agreement with sanofi for the acquisition of a sanofi portfolio of anti-inflammatory drugs
The concluded agreement is the result of a selective competitive process launched in 2020, which led Sanofi to choose Fidia among the various participating companies.
Based on this recent operation, the company has strengthened its presence in the prescription drug market, in addition to further expanding its range of products and specialities, thus consolidating its leadership in the Joint Care area and bolstering its business in Dermatology.
Investment in pharmaceutical core business
Fidia will acquire the registrations, trademarks, and related commercial rights of seven products (Urbason: oral and injectable, Esperson, Topicorte, Flubason and Dermatop: topical; Surgam: oral and suppositories; Flebocortid: injectable) that are leading brands within their segments, and have recorded worldwide sales of over 40 million euros in 2019.
Opportunity to strengthen international growth
The brands included in the agreement will be marketed in Europe (with a particular focus on Italy), Brazil, Morocco, Tunisia, Turkey, Lebanon, Thailand, and the countries of sub-Saharan Africa.
“The acquisition – explains Carlo Pizzocaro, President and CEO of Fidia Farmaceutici – confirms our will, despite the tough challenge created by Covid-19, to continue investing in core pharmaceutical business as part of our international growth, not only thanks to consolidation in the areas in which we are leaders, but also through more solid positioning as a result of entering different therapeutic areas. Furthermore, the acquisition represents an opportunity to strengthen managerial resources, under the framework of a sustainable annual average growth: once again, a development model that is characterised by the ability to face the challenges and seize the opportunities of tomorrow, in the long-term, although the world’s economies have been particularly battered.”